Vir Biotechnology (VIR) Stock Forecast & Price Target

Compare

1,439 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VIR Analyst Ratings

Strong Buy

7 Buy

0 Hold

0 Sell

Based on 7 analysts giving stock ratings to

Vir

Biotechnology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VIR Stock 12 Month Forecast

Average Price Target

$17.67

▲(166.52% Upside)

Based on 7 Wall Street analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $17.67 with a high forecast of $31.00 and a low forecast of $12.00. The average price target represents a 166.52% change from the last price of $6.63.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","11":"$11","18":"$18","25":"$25","32":"$32"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$17.67</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,11,18,25,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.07,7.987692307692308,9.905384615384616,11.823076923076922,13.740769230769232,15.658461538461538,17.576153846153844,19.493846153846153,21.411538461538463,23.32923076923077,25.246923076923075,27.164615384615384,29.08230769230769,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.07,6.962307692307693,7.854615384615386,8.746923076923078,9.639230769230771,10.531538461538464,11.423846153846155,12.316153846153847,13.20846153846154,14.100769230769233,14.993076923076925,15.885384615384618,16.77769230769231,{"y":17.67,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,6.07,6.526153846153846,6.9823076923076925,7.438461538461539,7.894615384615385,8.350769230769231,8.806923076923077,9.263076923076923,9.71923076923077,10.175384615384615,10.631538461538462,11.087692307692308,11.543846153846154,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":8.15,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.34,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$31.00

Average Price Target$17.67

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

$15

Buy

126.24%

Upside

Reiterated

12/12/25

H.C. Wainwright Sticks to Their Buy Rating for Vir Biotechnology (VIR)

Joseph Stringer

Needham

$14

Buy

111.16%

Upside

Reiterated

12/08/25

Vir Biotechnology's HDV Program: A Promising Investment Opportunity Amidst Market UnderappreciationWe believe VIR's HDV asset (elebsiran + tobevibart) has a best-in-class profile, supported by Ph2 data recently disclosed at the Nov 2025 AASLD meeting (note). We view the Bluejay acquisition as a positive readthrough to VIR given our view that 1) VIR's elebsiran/tobevibart profile is better than the deal, in addition to GILD's push to re-sbumit the bulevirtide sNDA (expected approval in 2026), signals very high interest in the HDV commercial opportunity in our view (MIRM ests. $750M+ in brelovitug peak revenue), and 3) the deal size is quite favorable for a potentially 3rd-to-market asset, in our view. We anticipate VIR to trade up today on the news and believe the company's HDV program is underappreciated by investors and is not adequately reflected in the stock (even with risk-adjusted revenues) at current levels.

Gena Wang

Barclays

$31

Buy

367.57%

Upside

Reiterated

11/11/25

Barclays Sticks to Their Buy Rating for Vir Biotechnology (VIR)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/10/25

Vir Biotechnology (VIR) Gets a Buy from TD Cowen

Michael Ulz

Morgan Stanley

$20

Buy

201.66%

Upside

Reiterated

11/10/25

Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)Reiterate Overweight.

Cory Kasimov

Evercore ISI

$12

Buy

81.00%

Upside

Reiterated

11/06/25

Evercore ISI Remains a Buy on Vir Biotechnology (VIR)

Alec Stranahan

Bank of America Securities

$14

Buy

111.16%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Their Buy Rating for Vir Biotechnology (VIR)We reiterate Buy and $14 PO as we see essentially no credit being given to the pipeline.

Sean McCutcheon

Raymond James

$12

Buy

81.00%

Upside

Reiterated

08/07/25

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Roanna Ruiz

Leerink Partners

$16

Buy

141.33%

Upside

Reiterated

08/06/25

Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating

Eric Joseph

J.P. Morgan

$14

Hold

111.16%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Paul Choi

Goldman Sachs

$28→$21

Buy

216.74%

Upside

Reiterated

04/16/25

Vir Biotechnology (VIR) PT Lowered to $21 at Goldman SachsGoldman Sachs analyst Paul Choi lowered the price target on Vir Biotechnology (NASDAQ: VIR) to $21.00 (from $28.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

$15

Buy

126.24%

Upside

Reiterated

12/12/25

H.C. Wainwright Sticks to Their Buy Rating for Vir Biotechnology (VIR)

Joseph Stringer

Needham

$14

Buy

111.16%

Upside

Reiterated

12/08/25

Gena Wang

Barclays

$31

Buy

367.57%

Upside

Reiterated

11/11/25

Barclays Sticks to Their Buy Rating for Vir Biotechnology (VIR)

Phil Nadeau

TD Cowen

―

Buy

―

Reiterated

11/10/25

Vir Biotechnology (VIR) Gets a Buy from TD Cowen

Michael Ulz

Morgan Stanley

$20

Buy

201.66%

Upside

Reiterated

11/10/25

Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)Reiterate Overweight.

Cory Kasimov

Evercore ISI

$12

Buy

81.00%

Upside

Reiterated

11/06/25

Evercore ISI Remains a Buy on Vir Biotechnology (VIR)

Alec Stranahan

Bank of America Securities

$14

Buy

111.16%

Upside

Reiterated

11/06/25

Bank of America Securities Sticks to Their Buy Rating for Vir Biotechnology (VIR)We reiterate Buy and $14 PO as we see essentially no credit being given to the pipeline.

Sean McCutcheon

Raymond James

$12

Buy

81.00%

Upside

Reiterated

08/07/25

Raymond James Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Roanna Ruiz

Leerink Partners

$16

Buy

141.33%

Upside

Reiterated

08/06/25

Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating

Eric Joseph

J.P. Morgan

$14

Hold

111.16%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Paul Choi

Goldman Sachs

$28→$21

Buy

216.74%

Upside

Reiterated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vir Biotechnology

1 Month

xxx

Success Rate

10/21 ratings generated profit

Average Return

-3.26%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 47.62% of your transactions generating a profit, with an average return of -3.26% per trade.

3 Months

xxx

Success Rate

9/21 ratings generated profit

Average Return

-13.38%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 42.86% of your transactions generating a profit, with an average return of -13.38% per trade.

1 Year

Gena WangBarclays

Success Rate

8/24 ratings generated profit

Average Return

-11.87%

reiterated a buy rating last month

Copying Gena Wang's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -11.87% per trade.

2 Years

xxx

Success Rate

5/21 ratings generated profit

Average Return

-27.08%

reiterated a xxx

rating yesterday

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 23.81% of your transactions generating a profit, with an average return of -27.08% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VIR Analyst Recommendation Trends

Rating

Aug 25

Sep 25

Oct 25

Nov 25

Dec 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, VIR has received 14 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. VIR average Analyst price target in the past 3 months is 17.67.

Each month's total comprises the sum of three months' worth of ratings.

VIR Financial Forecast

VIR Earnings Forecast

Next quarter’s earnings estimate for VIR is -$0.65 with a range of -$0.80 to -$0.16. The previous quarter’s EPS was -$1.17. VIR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Sales Forecast

Next quarter’s sales forecast for VIR is $1.42M with a range of $240.00K to $3.90M. The previous quarter’s sales results were $240.00K. VIR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Stock Forecast FAQ

What is VIR’s average 12-month price target, according to analysts?

Based on analyst ratings, Vir Biotechnology’s 12-month average price target is 17.67.

What is VIR’s upside potential, based on the analysts’ average price target?

Vir Biotechnology has 166.52% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VIR a Buy, Sell or Hold?

Vir Biotechnology has a consensus rating of Strong Buy which is based on 7 buy ratings, 0 hold ratings and 0 sell ratings.

What is Vir Biotechnology’s price target?

The average price target for Vir Biotechnology is 17.67. This is based on 7 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $31.00 ,the lowest forecast is $12.00. The average price target represents 166.52% Increase from the current price of $6.63.

What do analysts say about Vir Biotechnology?

Vir Biotechnology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 7 Wall Streets Analysts.

How can I buy shares of VIR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vir Biotechnology (VIR) Stock Forecast & Price Target

VIR Analyst Ratings

VIR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vir Biotechnology

VIR Analyst Recommendation Trends

VIR Financial Forecast

VIR Earnings Forecast

VIR Sales Forecast

VIR Stock Forecast FAQ

Detailed List of Analyst Forecasts